×
Cosmos Health (COSM) reported third quarter 2026 revenue of $16.68 million, down 2.5% year over year and slightly below the consensus estimate of $17.34 million. Nine-month revenue reached a record $53.6 million, up 18% from the same period in 2025, driven by its core operating segments.
The central target of $5.00 is a fallback objective derived from market structure and recovery discussion, not a published analyst consensus. At the latest verified close near $2.81 , reaching $5.00 requires a roughly 78% advance — a very large move.
Cosmos Health posted record nine-month revenue of $53.59 million , up 17.6% from $45.57 million a year earlier. Third-quarter gross margin improved to 12.6% , a 465-basis-point sequential jump from 7.96% in the prior quarter.
HKPD is the common stock of Cellyan Biotechnology Co., Ltd (formerly Hong Kong Pharma Digital Technology Holdings), a Hong Kong-based over-the-counter (OTC) pharmaceutical cross-border e-commerce supply chain operator — not an exchange-traded fund (ETF). The share price has declined roughly 31% over the last 30 days , from about $2.04 to about $1.40.
FocalTherics (FOCL) shares fell roughly 41% over the last 30 days, from about $4.37 to about $2.57, driven primarily by a third-quarter revenue shortfall and narrowed full-year guidance. The sharpest move followed the November 5, 2026 earnings report, when three Focal One capital-system sales slipped into the fourth quarter on hospital purchasing and financing timing.
LLY is a high-growth pharmaceutical leader riding exceptional momentum in its cardiometabolic (heart and metabolic health) franchise, while MCK is a diversified pharmaceutical distributor delivering steadier, lower-volatility performance. LLY has delivered materially stronger recent revenue growth and share-price momentum, while MCK offers a more defensive profile with a far lower beta (a measure of volatility versus the broader market).
ACH closed at $0.0857, down -35.08% from the previous close of $0.1320, with the selling concentrated in Monday's regular session before the shares were halted; the stock remains suspended. The catalyst was the NYSE's determination to commence delisting proceedings under Section 802.01D for "abnormally low selling price," announced at 4:00 p.m. ET with trading suspended immediately — the terminal step after continued-listing notices for the sub-$1 price and sub-$50 million market capitalization.
The stock dropped to $3.04 from the prior close of $3.17, a move of -4.10%, with the decline occurring in early regular-session trading after a -2.31% slide in the previous session. No verified news or fundamental catalyst found; the company has issued no fresh press release or filing since its November 5 earnings, and the drop is likely a continuation of post-earnings selling rather than a reaction to new information.
MEDS is the Nasdaq-listed common stock of DataMEDS AI, Inc. , a small-cap health IT company headquartered in Tampa, Florida. The company integrates technology, pharmacy, pharmaceutical-adjacent services, and telemedicine into a single healthcare platform.
MEDS fell -21.62% to $0.5811 from Friday's close of $0.7439, a decline recorded during Monday's regular trading session. The drop followed disclosure of an at-the-market sales agreement with Dawson James Securities, signed November 16 alongside a matching prospectus supplement, permitting shares to be sold into the market under the company's existing shelf.
COSM is the Nasdaq-listed ticker for Cosmos Health Inc., a diversified, vertically integrated global healthcare company headquartered in Thessaloniki, Greece. The company owns proprietary brands including Sky Premium Life, Mediterranation, bio-bebe, C-Sept, and C-Scrub, spanning nutraceuticals, pharmaceuticals, biocides, and medical devices.
Cosmos Health (COSM) fell -19.14%, or -$0.62, to $2.62 from Friday's close of $3.24, with the drop taking place during Monday's regular session. No verified news or fundamental catalyst found for Monday's move; it likely reflects continued post-reverse-split churn in a thinly traded micro-cap that has now declined in three of the last four sessions, against a typical daily swing of roughly 6.5%.
Cardinal Health (CAH) and Cencora (COR) are two of the three dominant U.S. pharmaceutical wholesale and distribution companies, which together with McKesson control more than 90% of the market. CAH has delivered stronger recent momentum, with consecutive earnings beats and raised guidance, while COR has shown comparatively flatter price action over the past year.
COSM slid from a previous close of $0.3049 to $0.2731, down -10.43%, during regular market hours on Monday. No verified news or fundamental catalyst found — the decline is consistent with profit-taking and the stock's routine volatility, having posted roughly nine single-day moves of ±10% or more over the last 60 sessions.
The $2.95 central stock price target is the arithmetic mean of two verified analyst targets: $1.40 from Noble Capital Markets and $4.50 from Zacks Small-Cap Research. The target range is unusually wide ($1.40 to $4.50), reflecting two very different valuation methods rather than a tight consensus.
ACH dropped -18.71% during regular market hours, sliding from a $0.2031 prior close to $0.1651. The decline extends the post-earnings selloff after Accendra's Nov 5 Q3 2026 miss — adjusted EPS of -$0.23 versus -$0.09 expected and revenue of $601.8M versus $617.4M — plus guidance cut to as much as 30% below the prior adjusted-EBITDA midpoint.
The $1.00 figure is not an analyst price target. It is the NYSE's minimum average share-price requirement that Accendra Health must regain to maintain its listing. With the stock trading near $0.20, reaching $1.00 would require a gain of roughly 400% — a very large move.
Specialty momentum is the core catalyst. Management has guided to double-digit specialty growth in fiscal 2027 after a roughly 25% surge in fiscal 2026, anchored by oncology, urology, and autoimmune (including gastroenterology) platforms. Earnings guidance points to 13%–15% growth. Cardinal Health guided fiscal 2027 non-GAAP EPS to $12.40–$12.60, above its longer-term 12%–14% EPS growth framework.
The central $300 target is the rounded average of verified analyst price targets above the current share price, not the all-analyst mean. At about $271.72, reaching $300 implies roughly 10% upside — a modest but still meaningful move.
Cardinal Health (CAH) rose roughly 14% over the trailing 30 days, climbing from about $237.57 (October 9) to $271.72 (November 6) and reaching a fresh 52-week high. The move was driven by a beat-and-raise fiscal Q1 2027 report: adjusted EPS of $3.26 versus a ~$2.94 consensus, and revenue of $67.51 billion versus ~$66.6 billion.